MX2023004537A - Compuestos y metodos para el tratamiento de trastornos oculares. - Google Patents
Compuestos y metodos para el tratamiento de trastornos oculares.Info
- Publication number
- MX2023004537A MX2023004537A MX2023004537A MX2023004537A MX2023004537A MX 2023004537 A MX2023004537 A MX 2023004537A MX 2023004537 A MX2023004537 A MX 2023004537A MX 2023004537 A MX2023004537 A MX 2023004537A MX 2023004537 A MX2023004537 A MX 2023004537A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- treatment
- inflammatory
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000022873 Ocular disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001530 keratinolytic effect Effects 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 229940124091 Keratolytic Drugs 0.000 abstract 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 208000010217 blepharitis Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000000744 eyelid Anatomy 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063094793P | 2020-10-21 | 2020-10-21 | |
| US202163170988P | 2021-04-05 | 2021-04-05 | |
| PCT/IB2021/000707 WO2022084738A2 (en) | 2020-10-21 | 2021-10-20 | Compounds and methods for the treatment of ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004537A true MX2023004537A (es) | 2023-06-15 |
Family
ID=81291739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004537A MX2023004537A (es) | 2020-10-21 | 2021-10-20 | Compuestos y metodos para el tratamiento de trastornos oculares. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4232149A4 (https=) |
| JP (1) | JP2023546453A (https=) |
| KR (1) | KR20230110515A (https=) |
| AU (1) | AU2021363702A1 (https=) |
| CA (1) | CA3196145A1 (https=) |
| IL (1) | IL302173A (https=) |
| MX (1) | MX2023004537A (https=) |
| WO (1) | WO2022084738A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7700045B2 (ja) | 2019-04-18 | 2025-06-30 | アズーラ オフサルミックス エルティーディー． | 眼障害を処置するための化合物および方法 |
| US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| WO2024100454A2 (en) * | 2022-11-11 | 2024-05-16 | Azura Ophthalmics Ltd. | Composition and methods for improving signs and symptoms of ocular disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1483579A4 (en) * | 2002-02-15 | 2006-07-12 | Merckle Gmbh | CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, PROCESS FOR THEIR MANUFACTURE AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF |
| CA2840626A1 (en) * | 2011-06-29 | 2013-01-03 | Insite Vision Incorporated | Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence |
| WO2018161039A1 (en) * | 2017-03-03 | 2018-09-07 | Synovo Gmbh | Novel anti-infective and anti-inflammatory compounds |
| WO2018215638A1 (en) * | 2017-05-26 | 2018-11-29 | Novaliq Gmbh | Pharmaceutical compositions comprising azithromycin |
| EP3955937A4 (en) * | 2019-04-18 | 2023-01-18 | Azura Ophthalmics Ltd. | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES |
-
2021
- 2021-10-20 IL IL302173A patent/IL302173A/en unknown
- 2021-10-20 WO PCT/IB2021/000707 patent/WO2022084738A2/en not_active Ceased
- 2021-10-20 JP JP2023524276A patent/JP2023546453A/ja active Pending
- 2021-10-20 AU AU2021363702A patent/AU2021363702A1/en not_active Abandoned
- 2021-10-20 CA CA3196145A patent/CA3196145A1/en active Pending
- 2021-10-20 KR KR1020237016470A patent/KR20230110515A/ko active Pending
- 2021-10-20 EP EP21882226.0A patent/EP4232149A4/en active Pending
- 2021-10-20 MX MX2023004537A patent/MX2023004537A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022084738A2 (en) | 2022-04-28 |
| EP4232149A2 (en) | 2023-08-30 |
| EP4232149A4 (en) | 2024-12-11 |
| WO2022084738A3 (en) | 2022-06-30 |
| AU2021363702A1 (en) | 2023-06-15 |
| CA3196145A1 (en) | 2022-04-28 |
| JP2023546453A (ja) | 2023-11-02 |
| KR20230110515A (ko) | 2023-07-24 |
| AU2021363702A9 (en) | 2024-02-08 |
| IL302173A (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004537A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| WO2020212760A3 (en) | Compounds and methods for the treatment of ocular disorders | |
| Jassim et al. | Crosstalk between dysfunctional mitochondria and inflammation in glaucomatous neurodegeneration | |
| MX2016014634A (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| MX2020003534A (es) | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| CL2025001153A1 (es) | Agentes de arni para inhibir la expresión de la proteína quinasa dm1 (dmpk) | |
| MX2024003580A (es) | Metodos de tratamiento de enfermedades inflamatorias oculares. | |
| BR112021025701A2 (pt) | Formulações e métodos de parasiticida de isoxazolina para tratar blefarite | |
| AR033151A1 (es) | Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares | |
| MX2023004539A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| MX2023004538A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| MX2022013665A (es) | Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares. | |
| EP3416617B1 (en) | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human | |
| MX2024012438A (es) | Inhibición de la histona deacetilasa 6 (hdac6) | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| AR092842A1 (es) | Tratamiento de enfermedades inflamatorias oculares usando laquinimod | |
| RU2020119228A (ru) | Соединения, композиции и способы лечения нарушений со стороны органа зрения и заболеваний кожи | |
| CL2025001428A1 (es) | Composiciones farmacéuticas para administración ocular | |
| RU2017111579A (ru) | Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина | |
| MX2023010918A (es) | Metodos y composiciones para el tratamiento de enfermedades oculares. | |
| BR112023022561A2 (pt) | Métodos e composições para o tratamento de retinopatia diabética e condições relacionadas | |
| Ben Yahia et al. | Comparative effect of topical diclofenac and topical dexamethasone on anterior chamber flare and postoperative pain following rhegmatogenous retinal detachment surgery | |
| Delval et al. | Safety and efficacy of unpreserved timolol 0.1% gel in patients controlled by preserved latanoprost with signs of ocular intolerance |